Posted BY: RM | NwoReport

WASHINGTON — A Texas lawsuit with a key deadline this month could threaten the nationwide availability of an abortion drug, which now accounts for the majority of abortions in the U.S.

The case filed by abortion opponents who helped challenge Roe v Wade seeks to reverse a decades-old approval by the Food and Drug Administration.

If a federal judge sides with them, it could halt the supply of the drug mifepristone in all states, both where abortion is banned and where it remains legal.

U.S. District Judge Matthew Kacsmaryk has not indicated exactly when or how he will rule, but groups like Timmaraju’s are preparing for a possible decision shortly after a Feb. 24 filing deadline.

Trending: CDC Adds Three-Dose COVID Jab To Childhood Vax List

The lawsuit was filed by the group Alliance Defending Freedom, which was also involved in the Mississippi case that led to Roe v. Wade being overturned.

“Our representatives in Congress created the FDA and gave the FDA the responsibility to make sure that drugs are safe before they’re allowed on the market … the FDA failed that responsibility,” said Julie Blake, senior counsel for the group.

They argue the FDA overstepped its authority in approving mifepristone by using an accelerated review process reserved for drugs to treat “serious or life-threatening illnesses.”

The FDA approved mifepristone — in combination with a second drug — as a safe and effective method for ending a pregnancy in 2000.

Kacsmaryk, who previously ruled against a program providing free birth control to minors in Texas, could also issue a ruling rolling back regulators’ decisions to ease restrictions on the pill’s availability.

In late 2021, the FDA removed a requirement that women pick up the drug in person. Last month the agency dropped another requirement that prevented most pharmacies from dispensing the pill.